Results 131 to 140 of about 86,323 (286)

Profile of olaparib in the treatment of advanced ovarian cancer

International Journal of Women's Health, 2016
Dana M Chase,1,2 Shreya Patel,2,3 Kristin Shields4 1Division of Gynecologic Oncology, The University of Arizona Cancer Center, 2Division of Gynecologic Oncology, 3Creighton University School of Medicine, St Joseph’s Hospital and Medical Center ...
Chase DM, Patel S, Shields K
doaj  

Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells.

Proceedings of the National Academy of Sciences of the United States of America, 1997
J. M. Murcia, C. Niedergang, C. Trucco, M. Ricoul, B. Dutrillaux, M. Mark, F. Oliver, M. Masson, A. Dierich, M. Lemeur, Caroline Walztinger, P. Chambon, G. Murcia   +12 more
semanticscholar   +1 more source

Optimizing the integration of modern systemic therapies and advanced radiotherapy techniques in breast cancer management: An expert opinion from the Institut Curie Breast Radiotherapy Group

International Journal of Cancer, Volume 158, Issue 7, Page 1775-1784, 1 April 2026.
Abstract The integration of modern systemic therapies with radiotherapy (RT) represents a promising strategy in breast cancer management, enhancing both locoregional control and systemic disease outcomes. This expert consensus from the Institut Curie Breast Radiotherapy Group focuses exclusively on modern systemic agents, synthesizing current evidence ...
Cezara Cheptea, Pierre Loap, Sofiane Allali, Alain Fourquet, Kim Cao, Youlia Kirova   +5 more
wiley   +1 more source

Clinical validation of a DNA methylation biomarker associated with overall survival of relapsed ovarian cancer patients

International Journal of Cancer, Volume 158, Issue 7, Page 1821-1835, 1 April 2026.
What's new? Most patients with ovarian cancer (OC) relapse after first‐line chemotherapy, and prognosis with second‐line treatment depends largely on the platinum‐free interval. However, reliable biomarkers to predict response to second‐line therapy remain lacking.
Muhammad Habiburrahman, Nahal Masrour, Naina Patel, Anna M. Piskorz, Robert Brown, James D. Brenton, Iain A. McNeish, James M. Flanagan   +7 more
wiley   +1 more source

Olaparib for patients with tumors harboring alterations in homologous recombination repair genes: Results from the drug rediscovery protocol

International Journal of Cancer, Volume 158, Issue 6, Page 1617-1627, 15 March 2026.
What's new? PARP inhibitors are effective in patients with inactivating alterations in the BRCA1/2 genes across tumor types. However, the efficacy of PARP inhibitors in patients with other inactivated homologous recombination repair genes remains unclear. This knowledge gap and discrepancies in EMA/FDA approvals highlight the need for better biomarkers.
Ilse A. C. Spiekman, Niven Mehra, Laurien J. Zeverijn, Birgit S. Geurts, Karlijn Verkerk, Soemeya F. Haj Mohammad, Vincent van der Noort, Paul Roepman, Wendy W. J. de Leng, Anne M. L. Jansen, Addy C. M. van de Luijtgaarden, Theo van Voorthuizen, Tineke E. Buffart, Hans Gelderblom, Emile E. Voest, Henk M. W. Verheul   +15 more
wiley   +1 more source

Poly [ADP-Ribose] Polymerase 1 [PDF]

, 2020
openaire   +1 more source

Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib

Clinical Pharmacology &Therapeutics, Volume 119, Issue 3, Page 618-628, March 2026.
We present model‐informed selection of the recommended dose for expansion (RDE) of investigational oral ATR inhibitor tuvusertib, by integrating clinical pharmacokinetics (PK), pharmacodynamics (PD), and safety data from DDRiver Solid Tumors 301 trial Part A1 (NCT04170153).
Jatinder Kaur Mukker, Paul Matthias Diderichsen, Farina Hellmann, Timothy A. Yap, Ruth Plummer, Anthony W. Tolcher, Johann S. de Bono, Ioannis Gounaris, Zoltan Szucs, Astrid Zimmermann, Irina Kareva, Jayaprakasam Bolleddula, Annick Seithel‐Keuth, Giuseppe Locatelli, Marta Enderlin, Christine Hicking, Anup Zutshi, Wei Gao, Rainer Strotmann, Lisa Benincosa, Karthik Venkatakrishnan   +20 more
wiley   +1 more source

Drastic Response to Olaparib in a Patient With Metastatic Castration‐Resistant Prostate Cancer Harboring BRCA2 Alterations and Near‐Threshold Tumor Mutational Burden

IJU Case Reports, Volume 9, Issue 2, March 2026.
ABSTRACT Introduction BRCA2 alterations and high tumor mutational burden (TMB‐H) are responsible for prostate cancer; however, their co‐occurrence is uncommon, and evidence for PARP inhibition in the castration‐sensitive setting remains limited. We describe a case of metastatic castration‐resistant prostate cancer (CRPC) harboring both biomarkers ...
Kotaro Yokota, Takeo Kosaka, Tatsuaki Daimon, Shinnosuke Fujiwara, Kohei Nakamura, Hiroshi Nishihara, Mototsugu Oya   +6 more
wiley   +1 more source

PARP (poly[ADP-ribose] polymerase) [PDF]

, 2012
openaire   +2 more sources

Antitumor activity and structure-activity relationship of poly (ADP-ribose) polymerase (PARP)-based dual inhibitors. [PDF]

J Enzyme Inhib Med Chem
Yang C, Shang Y, Li X, Li J, Li H, Han J.   +5 more
europepmc   +1 more source